<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" class="marks" width="995" height="552" viewBox="0 0 995 552"><rect width="995" height="552" fill="white"/><g fill="none" stroke-miterlimit="10" transform="translate(52,27)"><g class="mark-group role-frame root" role="graphics-object" aria-roledescription="group mark container"><g transform="translate(0,0)"><path class="background" aria-hidden="true" d="M0.5,0.5h800v400h-800Z" stroke="#ddd"/><g><g class="mark-group role-axis" aria-hidden="true"><g transform="translate(0.5,0.5)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-rule role-axis-grid" pointer-events="none"><line transform="translate(0,400)" x2="800" y2="0" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(0,371)" x2="800" y2="0" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(0,343)" x2="800" y2="0" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(0,314)" x2="800" y2="0" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(0,286)" x2="800" y2="0" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(0,257)" x2="800" y2="0" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(0,229)" x2="800" y2="0" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(0,200)" x2="800" y2="0" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(0,171)" x2="800" y2="0" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(0,143)" x2="800" y2="0" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(0,114)" x2="800" y2="0" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(0,86)" x2="800" y2="0" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(0,57)" x2="800" y2="0" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(0,29)" x2="800" y2="0" stroke="#ddd" stroke-width="1" opacity="1"/><line transform="translate(0,0)" x2="800" y2="0" stroke="#ddd" stroke-width="1" opacity="1"/></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-group role-axis" role="graphics-symbol" aria-roledescription="axis" aria-label="X-axis titled 'Medication' for a discrete scale with 12 values: acarbose, repaglinide, nateglinide, glipizide, rosiglitazone, ending with metformin"><g transform="translate(0.5,400.5)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-rule role-axis-tick" pointer-events="none"><line transform="translate(39,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(104,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(170,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(236,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(301,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(367,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(432,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(498,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(563,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(629,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(695,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(760,0)" x2="0" y2="5" stroke="#888" stroke-width="1" opacity="1"/></g><g class="mark-text role-axis-label" pointer-events="none"><text text-anchor="end" transform="translate(38.844262295081975,7) rotate(-45) translate(0,11)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">acarbose</text><text text-anchor="end" transform="translate(104.41803278688525,7) rotate(-45) translate(0,11)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">repaglinide</text><text text-anchor="end" transform="translate(169.9918032786885,7) rotate(-45) translate(0,11)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">nateglinide</text><text text-anchor="end" transform="translate(235.56557377049182,7) rotate(-45) translate(0,11)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">glipizide</text><text text-anchor="end" transform="translate(301.1393442622951,7) rotate(-45) translate(0,11)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">rosiglitazone</text><text text-anchor="end" transform="translate(366.71311475409834,7) rotate(-45) translate(0,11)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">pioglitazone</text><text text-anchor="end" transform="translate(432.28688524590166,7) rotate(-45) translate(0,11)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">glyburide-metformin</text><text text-anchor="end" transform="translate(497.8606557377049,7) rotate(-45) translate(0,11)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">glimepiride</text><text text-anchor="end" transform="translate(563.4344262295082,7) rotate(-45) translate(0,11)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">insulin</text><text text-anchor="end" transform="translate(629.0081967213115,7) rotate(-45) translate(0,11)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">chlorpropamide</text><text text-anchor="end" transform="translate(694.5819672131147,7) rotate(-45) translate(0,11)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">glyburide</text><text text-anchor="end" transform="translate(760.155737704918,7) rotate(-45) translate(0,11)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">metformin</text></g><g class="mark-rule role-axis-domain" pointer-events="none"><line transform="translate(0,0)" x2="800" y2="0" stroke="#888" stroke-width="1" opacity="1"/></g><g class="mark-text role-axis-title" pointer-events="none"><text text-anchor="middle" transform="translate(400,117.37564721584081)" font-family="sans-serif" font-size="11px" font-weight="bold" fill="#000" opacity="1">Medication</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-group role-axis" role="graphics-symbol" aria-roledescription="axis" aria-label="Y-axis titled 'Readmission Rate' for a linear scale with values from 0.0 to 0.7"><g transform="translate(0.5,0.5)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-rule role-axis-tick" pointer-events="none"><line transform="translate(0,400)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,371)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,343)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,314)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,286)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,257)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,229)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,200)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,171)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,143)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,114)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,86)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,57)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,29)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/><line transform="translate(0,0)" x2="-5" y2="0" stroke="#888" stroke-width="1" opacity="1"/></g><g class="mark-text role-axis-label" pointer-events="none"><text text-anchor="end" transform="translate(-7,400) rotate(-45) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">0.00</text><text text-anchor="end" transform="translate(-7,371.42857142857144) rotate(-45) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="0">0.05</text><text text-anchor="end" transform="translate(-7,342.85714285714283) rotate(-45) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">0.10</text><text text-anchor="end" transform="translate(-7,314.2857142857143) rotate(-45) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="0">0.15</text><text text-anchor="end" transform="translate(-7,285.71428571428567) rotate(-45) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">0.20</text><text text-anchor="end" transform="translate(-7,257.1428571428571) rotate(-45) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="0">0.25</text><text text-anchor="end" transform="translate(-7,228.57142857142856) rotate(-45) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">0.30</text><text text-anchor="end" transform="translate(-7,200) rotate(-45) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="0">0.35</text><text text-anchor="end" transform="translate(-7,171.4285714285714) rotate(-45) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">0.40</text><text text-anchor="end" transform="translate(-7,142.85714285714283) rotate(-45) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="0">0.45</text><text text-anchor="end" transform="translate(-7,114.28571428571428) rotate(-45) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">0.50</text><text text-anchor="end" transform="translate(-7,85.71428571428568) rotate(-45) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="0">0.55</text><text text-anchor="end" transform="translate(-7,57.14285714285712) rotate(-45) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">0.60</text><text text-anchor="end" transform="translate(-7,28.571428571428513) rotate(-45) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="0">0.65</text><text text-anchor="end" transform="translate(-7,0) rotate(-45) translate(0,4)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">0.70</text></g><g class="mark-rule role-axis-domain" pointer-events="none"><line transform="translate(0,400)" x2="0" y2="-400" stroke="#888" stroke-width="1" opacity="1"/></g><g class="mark-text role-axis-title" pointer-events="none"><text text-anchor="middle" transform="translate(-35.21702618770726,200) rotate(-90) translate(0,-2)" font-family="sans-serif" font-size="11px" font-weight="bold" fill="#000" opacity="1">Readmission Rate</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-rect role-mark marks" role="graphics-object" aria-roledescription="rect mark container"><path aria-label="Medication: metformin; Readmission Rate: 0.431978571061; status: Prescribed; Medication Status: Prescribed; Status: Prescribed; Number of Patients: 19,413" role="graphics-symbol" aria-roledescription="bar" d="M760.655737704918,153.15510225106888h26.229508196721312v246.84489774893112h-26.229508196721312Z" fill="#58c782"/><path aria-label="Medication: metformin; Readmission Rate: 0.46781530485; status: Not Prescribed; Medication Status: Not Prescribed; Status: Not Prescribed; Number of Patients: 81,778" role="graphics-symbol" aria-roledescription="bar" d="M734.4262295081967,132.67696865730568h26.229508196721312v267.3230313426943h-26.229508196721312Z" fill="#8f8f8f"/><path aria-label="Medication: repaglinide; Readmission Rate: 0.550870147256; status: Prescribed; Medication Status: Prescribed; Status: Prescribed; Number of Patients: 1,494" role="graphics-symbol" aria-roledescription="bar" d="M104.91803278688525,85.21705871103462h26.229508196721312v314.7829412889654h-26.229508196721312Z" fill="#58c782"/><path aria-label="Medication: repaglinide; Readmission Rate: 0.459526873996; status: Not Prescribed; Medication Status: Not Prescribed; Status: Not Prescribed; Number of Patients: 100,227" role="graphics-symbol" aria-roledescription="bar" d="M78.68852459016394,137.41321485941197h26.229508196721312v262.58678514058806h-26.229508196721312Z" fill="#8f8f8f"/><path aria-label="Medication: nateglinide; Readmission Rate: 0.486994219653; status: Prescribed; Medication Status: Prescribed; Status: Prescribed; Number of Patients: 692" role="graphics-symbol" aria-roledescription="bar" d="M170.4918032786885,121.7175887696119h26.229508196721312v278.2824112303881h-26.229508196721312Z" fill="#58c782"/><path aria-label="Medication: nateglinide; Readmission Rate: 0.46070272998; status: Not Prescribed; Medication Status: Not Prescribed; Status: Not Prescribed; Number of Patients: 101,063" role="graphics-symbol" aria-roledescription="bar" d="M144.2622950819672,136.74129715410896h26.229508196721312v263.25870284589104h-26.229508196721312Z" fill="#8f8f8f"/><path aria-label="Medication: chlorpropamide; Readmission Rate: 0.458823529412; status: Prescribed; Medication Status: Prescribed; Status: Prescribed; Number of Patients: 85" role="graphics-symbol" aria-roledescription="bar" d="M629.5081967213115,137.81512605042016h26.229508196721312v262.1848739495798h-26.229508196721312Z" fill="#58c782"/><path aria-label="Medication: chlorpropamide; Readmission Rate: 0.460887096774; status: Not Prescribed; Medication Status: Not Prescribed; Status: Not Prescribed; Number of Patients: 101,680" role="graphics-symbol" aria-roledescription="bar" d="M603.2786885245902,136.6359447004608h26.229508196721312v263.3640552995392h-26.229508196721312Z" fill="#8f8f8f"/><path aria-label="Medication: glimepiride; Readmission Rate: 0.469081448869; status: Prescribed; Medication Status: Prescribed; Status: Prescribed; Number of Patients: 4,997" role="graphics-symbol" aria-roledescription="bar" d="M498.3606557377049,131.95345778895907h26.229508196721312v268.0465422110409h-26.229508196721312Z" fill="#58c782"/><path aria-label="Medication: glimepiride; Readmission Rate: 0.460419363189; status: Not Prescribed; Medication Status: Not Prescribed; Status: Not Prescribed; Number of Patients: 96,575" role="graphics-symbol" aria-roledescription="bar" d="M472.1311475409836,136.90322103472505h26.229508196721312v263.09677896527495h-26.229508196721312Z" fill="#8f8f8f"/><path aria-label="Medication: glipizide; Readmission Rate: 0.48540326571; status: Prescribed; Medication Status: Prescribed; Status: Prescribed; Number of Patients: 12,126" role="graphics-symbol" aria-roledescription="bar" d="M236.06557377049182,122.62670530854595h26.229508196721312v277.373294691454h-26.229508196721312Z" fill="#58c782"/><path aria-label="Medication: glipizide; Readmission Rate: 0.457117198024; status: Not Prescribed; Medication Status: Not Prescribed; Status: Not Prescribed; Number of Patients: 89,080" role="graphics-symbol" aria-roledescription="bar" d="M209.8360655737705,138.7901725575726h26.229508196721312v261.2098274424274h-26.229508196721312Z" fill="#8f8f8f"/><path aria-label="Medication: glyburide; Readmission Rate: 0.453599048186; status: Prescribed; Medication Status: Prescribed; Status: Prescribed; Number of Patients: 10,086" role="graphics-symbol" aria-roledescription="bar" d="M695.0819672131147,140.80054389394067h26.229508196721312v259.1994561060593h-26.229508196721312Z" fill="#58c782"/><path aria-label="Medication: glyburide; Readmission Rate: 0.461521576891; status: Not Prescribed; Medication Status: Not Prescribed; Status: Not Prescribed; Number of Patients: 91,116" role="graphics-symbol" aria-roledescription="bar" d="M668.8524590163934,136.2733846337165h26.229508196721312v263.7266153662835h-26.229508196721312Z" fill="#8f8f8f"/><path aria-label="Medication: pioglitazone; Readmission Rate: 0.480998613037; status: Prescribed; Medication Status: Prescribed; Status: Prescribed; Number of Patients: 7,210" role="graphics-symbol" aria-roledescription="bar" d="M367.21311475409834,125.14364969288683h26.229508196721312v274.8563503071132h-26.229508196721312Z" fill="#58c782"/><path aria-label="Medication: pioglitazone; Readmission Rate: 0.459253690252; status: Not Prescribed; Medication Status: Not Prescribed; Status: Not Prescribed; Number of Patients: 94,438" role="graphics-symbol" aria-roledescription="bar" d="M340.983606557377,137.56931985611115h26.229508196721312v262.4306801438888h-26.229508196721312Z" fill="#8f8f8f"/><path aria-label="Medication: rosiglitazone; Readmission Rate: 0.485345651481; status: Prescribed; Medication Status: Prescribed; Status: Prescribed; Number of Patients: 6,278" role="graphics-symbol" aria-roledescription="bar" d="M301.6393442622951,122.65962772493512h26.229508196721312v277.34037227506485h-26.229508196721312Z" fill="#58c782"/><path aria-label="Medication: rosiglitazone; Readmission Rate: 0.459408182304; status: Not Prescribed; Medication Status: Not Prescribed; Status: Not Prescribed; Number of Patients: 95,401" role="graphics-symbol" aria-roledescription="bar" d="M275.40983606557376,137.48103868333214h26.229508196721312v262.51896131666786h-26.229508196721312Z" fill="#8f8f8f"/><path aria-label="Medication: acarbose; Readmission Rate: 0.593442622951; status: Prescribed; Medication Status: Prescribed; Status: Prescribed; Number of Patients: 305" role="graphics-symbol" aria-roledescription="bar" d="M39.344262295081975,60.88992974238878h26.229508196721312v339.1100702576112h-26.229508196721312Z" fill="#58c782"/><path aria-label="Medication: acarbose; Readmission Rate: 0.460476256185; status: Not Prescribed; Medication Status: Not Prescribed; Status: Not Prescribed; Number of Patients: 101,458" role="graphics-symbol" aria-roledescription="bar" d="M13.114754098360663,136.87071075152843h26.229508196721312v263.12928924847154h-26.229508196721312Z" fill="#8f8f8f"/><path aria-label="Medication: insulin; Readmission Rate: 0.468326811336; status: Prescribed; Medication Status: Prescribed; Status: Prescribed; Number of Patients: 42,165" role="graphics-symbol" aria-roledescription="bar" d="M563.9344262295082,132.38467923633343h26.229508196721312v267.61532076366655h-26.229508196721312Z" fill="#58c782"/><path aria-label="Medication: insulin; Readmission Rate: 0.436971065572; status: Not Prescribed; Medication Status: Not Prescribed; Status: Not Prescribed; Number of Patients: 47,383" role="graphics-symbol" aria-roledescription="bar" d="M537.7049180327868,150.3022482445482h26.229508196721312v249.6977517554518h-26.229508196721312Z" fill="#8f8f8f"/><path aria-label="Medication: glyburide-metformin; Readmission Rate: 0.478571428571; status: Prescribed; Medication Status: Prescribed; Status: Prescribed; Number of Patients: 700" role="graphics-symbol" aria-roledescription="bar" d="M432.78688524590166,126.53061224489792h26.229508196721312v273.46938775510205h-26.229508196721312Z" fill="#58c782"/><path aria-label="Medication: glyburide-metformin; Readmission Rate: 0.460775776766; status: Not Prescribed; Medication Status: Not Prescribed; Status: Not Prescribed; Number of Patients: 101,060" role="graphics-symbol" aria-roledescription="bar" d="M406.55737704918033,136.69955613355575h26.229508196721312v263.30044386644425h-26.229508196721312Z" fill="#8f8f8f"/></g><g class="mark-group role-legend" role="graphics-symbol" aria-roledescription="legend" aria-label="Symbol legend titled 'Medication Status' for fill color with 2 values: Not Prescribed, Prescribed"><g transform="translate(818,0)"><path class="background" aria-hidden="true" d="M0,0h120v49h-120Z" pointer-events="none"/><g><g class="mark-group role-legend-entry"><g transform="translate(0,19)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-group role-scope" role="graphics-object" aria-roledescription="group mark container"><g transform="translate(0,0)"><path class="background" aria-hidden="true" d="M0,0h110.5927734375v14h-110.5927734375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(7,7)" d="M-5,-5h10v10h-10Z" fill="#8f8f8f" stroke-width="1.5" opacity="1"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(18,11)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">Not Prescribed</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g><g transform="translate(0,16)"><path class="background" aria-hidden="true" d="M0,0h110.5927734375v14h-110.5927734375Z" pointer-events="none" opacity="1"/><g><g class="mark-symbol role-legend-symbol" pointer-events="none"><path transform="translate(7,7)" d="M-5,-5h10v10h-10Z" fill="#58c782" stroke-width="1.5" opacity="1"/></g><g class="mark-text role-legend-label" pointer-events="none"><text text-anchor="start" transform="translate(18,11)" font-family="sans-serif" font-size="14px" fill="#000" opacity="1">Prescribed</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-text role-legend-title" pointer-events="none"><text text-anchor="start" transform="translate(0,11)" font-family="sans-serif" font-size="14px" font-weight="bold" fill="#000" opacity="1">Medication Status</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g><g class="mark-group role-title"><g transform="translate(400,-21.949747468305834)"><path class="background" aria-hidden="true" d="M0,0h0v0h0Z" pointer-events="none"/><g><g class="mark-text role-title-text" role="graphics-symbol" aria-roledescription="title" aria-label="Title text 'Readmission Rates: Not Prescribed vs Prescribed'" pointer-events="none"><text text-anchor="middle" transform="translate(0,10)" font-family="sans-serif" font-size="13px" font-weight="bold" fill="#000" opacity="1">Readmission Rates: Not Prescribed vs Prescribed</text></g></g><path class="foreground" aria-hidden="true" d="" pointer-events="none" display="none"/></g></g></g><path class="foreground" aria-hidden="true" d="" display="none"/></g></g></g></svg>